DERI HASTALIKLARI VE FRENGI ARSIVI, vol.51, no.4, pp.124-128, 2017 (ESCI)
Background and Design: In the era of biological therapies, omalizumab (OMZ), a monoclonal antibody which inhibits IgE, has been postulated to be effective in the treatment of bullous pemphigoid (BP). We report our dinical experience with the use of OMZ in the treatment of BR